U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H14ClNO
Molecular Weight 223.699
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORKETAMINE

SMILES

c1ccc(c(c1)C2(CCCCC2=O)N)Cl

InChI

InChIKey=BEQZHFIKTBVCAU-UHFFFAOYSA-N
InChI=1S/C12H14ClNO/c13-10-6-2-1-5-9(10)12(14)8-4-3-7-11(12)15/h1-2,5-6H,3-4,7-8,14H2

HIDE SMILES / InChI
Norketamine is one of the major metabolites of Ketamine, which is routinely used as an anesthetic. Norketamine is a potent antagonist of the N-methyl-D-aspartate receptor and is believed to contribute to the analgesic effects of ketamine. In animal models, norketamine has been noted to increase the glomerular filtration rate by remodeling the cellular cytoskeleton, and it has been identified as having possible antidepressant effects.

Originator

Curator's Comment:: European Journal of Pharmacology Volume 49, Issue 1, 1 May 1978, Pages 15-23

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.7 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Pharmacokinetics and analgesic effects of i.m. and oral ketamine.
1981 Aug
Family history of cancer and mortality among patients gastrectomized because of benign gastric diseases.
1990 Jul
Interaction between morphine and norketamine enantiomers in rodent models of nociception.
2008 Oct
Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier.
2009 Sep
(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.
2014 Jul
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: It should be noted that this dosage is approximately 20 times less than the metabolic dose when ketamine is administered as an anesthetic. https://www.ncbi.nlm.nih.gov/pubmed/17439422
Balb/c mice were treated with norketamine for 3 days at a dose of 0.3 mg/100g delivered by intraperitoneal injection. Urinary excretion of albumin and creatine were both increased over the next 24 hours.
Route of Administration: Intraperitoneal
Podocyte cells were cultured and extracted from rat Kidneys. Cells were cultured for 1 week with collagen type IV at 37°C in 5% CO2 atmosphere. An NMDA receptor blockade was established by adding 50 microM of Norketamine Hydrochloride to the cell media. After 30 minutes a profound remodeling of podocyte cytoskeleton was observed, highlighted by the disappearance of actin stress fibers and redistribution of myosin-IIA. When the same concentration of norketamine was added to isolated rat glomeruli there was a significant increase in glomerular albumin permeability.
Name Type Language
NORKETAMINE
Common Name English
J397.916D
Code English
(+/-)-NORKETAMINE
Common Name English
2-AMINO-2-(O-CHLOROPHENYL)CYCLOHEXANONE
Common Name English
N-DEMETHYLKETAMINE
Common Name English
CYCLOHEXANONE, 2-AMINO-2-(2-CHLOROPHENYL)-
Systematic Name English
N-DESMETHYLKETAMINE
Common Name English
Code System Code Type Description
CAS
65329-10-4
Created by admin on Sat Jun 26 15:49:20 UTC 2021 , Edited by admin on Sat Jun 26 15:49:20 UTC 2021
SUPERSEDED
CAS
35211-10-0
Created by admin on Sat Jun 26 15:49:20 UTC 2021 , Edited by admin on Sat Jun 26 15:49:20 UTC 2021
PRIMARY
PUBCHEM
123767
Created by admin on Sat Jun 26 15:49:20 UTC 2021 , Edited by admin on Sat Jun 26 15:49:20 UTC 2021
PRIMARY
WIKIPEDIA
NORKETAMINE
Created by admin on Sat Jun 26 15:49:20 UTC 2021 , Edited by admin on Sat Jun 26 15:49:20 UTC 2021
PRIMARY
FDA UNII
XQY6JVF94X
Created by admin on Sat Jun 26 15:49:20 UTC 2021 , Edited by admin on Sat Jun 26 15:49:20 UTC 2021
PRIMARY